Download the BIF eBrochure
Download the 2014 Program Schedule
BIO Investor Forum Statistics
71% of all U.S. therapeutic companies that have had an IPO in 2013 have attended the BIO Investor Forum at least once in the past four years.
Last year’s conference scheduled more than 900 meetings.
Nearly 80% of all requests were between biotech companies and investors.
The event hosted 120 late-stage private and emerging public company presentations.
34% of all U.S. therapeutic IPO companies since 2012 attended BIO Investor Forum as a private company.
What People are Saying About the BIO Investor Forum
"For us, the BIO Investor Forum is the bellwether of life science investing and business creation. As such, it's the "must go to" meeting on our calendar each year." - Graeme Martin, CEO, Takeda Ventures
“The BIO Investor Forum over the years has proved to be an excellent venue for investors to interact with a high quality group of emerging biotechnology companies and their senior management teams. The ongoing exposure to the investor community is invaluable to this group of companies as they execute their business strategies, achieve significant clinical catalysts and ultimately look to the capital markets to fund their continued advancement. Given my experience over the years, I have found this well-orchestrated conference to be a “must-attend” annual event.” - John Chambers, ROTH Capital Partners